Campbell McInnes to Proto-Oncogene Proteins
This is a "connection" page, showing publications Campbell McInnes has written about Proto-Oncogene Proteins.
Connection Strength
3.344
-
Structure-activity and mechanistic studies of non-peptidic inhibitors of the PLK1 polo box domain identified through REPLACE. Eur J Med Chem. 2022 Jan 05; 227:113926.
Score: 0.633
-
Peptidomimetic Polo-Box-Targeted Inhibitors that Engage PLK1 in Tumor Cells and Are Selective against the PLK3 Tumor Suppressor. ChemMedChem. 2020 06 17; 15(12):1058-1066.
Score: 0.571
-
The Meisenheimer Complex as a Paradigm in Drug Discovery: Reversible Covalent Inhibition through C67 of the ATP Binding Site of PLK1. Cell Chem Biol. 2018 09 20; 25(9):1107-1116.e4.
Score: 0.504
-
Current assessment of polo-like kinases as anti-tumor drug targets. Expert Opin Drug Discov. 2014 Jul; 9(7):773-89.
Score: 0.378
-
Targeting subcellular localization through the polo-box domain: non-ATP competitive inhibitors recapitulate a PLK1 phenotype. Mol Cancer Ther. 2012 Aug; 11(8):1683-92.
Score: 0.334
-
PLK1 as an oncology target: current status and future potential. Drug Discov Today. 2011 Jul; 16(13-14):619-25.
Score: 0.307
-
Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov; 2(11):608-17.
Score: 0.223
-
Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. Chem Biol. 2004 Apr; 11(4):525-34.
Score: 0.187
-
Nonpeptidic, Polo-Box Domain-Targeted Inhibitors of PLK1 Block Kinase Activity, Induce Its Degradation and Target-Resistant Cells. J Med Chem. 2021 07 22; 64(14):9916-9925.
Score: 0.155
-
Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. J Mol Biol. 2005 Jul 15; 350(3):587-98.
Score: 0.051